Nivolumab (Opdivo) for unresectable or metastatic bladder cancer
Jump to navigation
Jump to search
Regimen in use at
- Nivolumab in all diseases (transclusion) (← links)
- Nivolumab for unresectable or metastatic bladder cancer (redirect page) (← links)
Regimen
| Study | Evidence | Efficacy | Pt Population |
|---|---|---|---|
| Sharma et al. 2017 (CheckMate 275) | Phase 2 (RT) | 19.6% overall PD-L1 expression ≥5%: 28.4% PD-L1 expression ≥1%: 23.8% PD-L1 expression less than 1%: 16.1% |
Prior treatment with least one platinum-based therapy |
Immunotherapy
- Nivolumab (Opdivo) 3 mg/kg IV once on day 1
- The FDA-approved dose which is listed in the package insert is 240 mg IV over 60 minutes once on day 1
14-day cycles
References
- CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25. link to original article contains dosing details in abstract PubMed